Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) meeting
the following criteria:

- Any histology

- Stage IIIB-IV disease

- Newly diagnosed or recurrent disease (after surgery or radical radiotherapy) proven
on cytology or histology before induction chemotherapy

- In case of adjuvant chemotherapy after previous surgery, time interval from
start of previous treatment to induction chemotherapy for metastatic disease is
12 months

- May or may not have measurable disease as defined by RECIST criteria

- Must not have progressed during the 4 courses of initial chemotherapy

- For patient presenting with measurable disease, there must be documented
radiographic evidence of response (complete response, partial response, or
stable disease) according to RECIST 1.1 criteria

- For patients without measurable disease, there must be no symptomatic/clinical
progression

- EGFR wild-type or unknown (known EGFR mutations are not eligible)

- Brain metastases allowed provided they are controlled and the patient must present
with a performance status (PS) of 0-1 after the 4 courses of chemotherapy and at
least 1 week off steroids

- No known endobronchial lesions and/or lesions infiltrating major pulmonary vessels
that increase the risk of pulmonary hemorrhage, including any of the following:

- Large protruding endobronchial lesions in the main or lobar bronchi

- Endobronchial lesions in the segmented bronchi are allowed

- Lesions extensively infiltrating the main or lobar bronchi

- Minor infiltrations in the wall of the bronchi are allowed

- Lesions infiltrating major pulmonary vessels (contiguous tumor and vessels)

- Tumors touching but not infiltrating (abutting) the vessels are acceptable

PATIENT CHARACTERISTICS:

- WHO performance status (PS) 0-2

- PS 2 capped at 15% of the study population

- Elderly population (i.e., > 70 years old) capped at 15% and must be PS 0-1

- Life expectancy ≥ 12 weeks

- ANC ≥ 1.5 x 10^9/L

- Platelet count ≥ 100 x 10^9/L

- Hemoglobin ≥ 9 g/dL

- PT or INR ≤ 1.2 times upper limit of normal (ULN)

- PTT ≤ 1.2 times ULN

- Bilirubin ≤ 1.5 times ULN

- AST/ALT ≤ 2.5 times ULN

- Serum creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 50 mL/min

- Urine protein:creatinine ratio ≤ 1 OR ≤ 1.0 g of protein by 24-hour urine collection

- May only be randomized in this trial once

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception 2 weeks prior to, during, and for
at least 1 month after completion of study therapy

- Corrected QT interval (QTc) ≤ 480 msec on normal 12-lead ECG

- If QTc interval is > 480 msec, then 2 additional ECGs should be obtained over a
brief period of time (e.g., within 15-20 minutes) to confirm the abnormality and
the average QTc interval will be determined from the 3 ECG tracings by manual
evaluation and will be used to determine if the patient will be excluded from
the study

- No history of any of the following cardiovascular conditions within the past 6
months:

- Cardiac angioplasty or stenting myocardial infarction

- Unstable angina

- Coronary artery bypass graft surgery

- Symptomatic peripheral vascular disease

- No NYHA class III-IV congestive heart failure (no class II, III, or IV for elderly
patients)

- LVEF normal

- No other malignancy within the past 2 years except for non-small cell lung cancer

- No poorly controlled hypertension, defined as blood pressure (BP) > 140/90 mm Hg

- Initiation or adjustment of antihypertensive medications is permitted prior to
study entry provided blood pressure is reassessed on two occasions that are
separated by a minimum of 1 hour and the mean systolic BP/diastolic BP values
must be ≤ 140/90 mm Hg

- No cerebrovascular accident (at any time in the past), transient ischemic attack,
deep venous thrombosis (DVT), or pulmonary embolism within the past 6 months

- Patients with recent DVT who have been treated with therapeutic anticoagulating
agents and remained stable for at least 6 weeks are eligible

- No hemoptysis within the past 6 weeks (patients with a history of hemoptysis
associated with metastatic disease must undergo a bronchoscopy to rule out
endobronchial lesions and patients with an endobronchial lesion will be excluded from
the study)

- No history of clinically significant gastrointestinal disorders, including any of the
following:

- Malabsorption syndrome

- Major resection of the stomach or small bowel that could affect the absorption
of the study drug

- Active peptic ulcer disease

- Known intraluminal metastatic lesions with risk of bleeding

- Inflammatory bowel disease

- Ulcerative colitis

- Other gastrointestinal conditions with increased risk of perforation

- No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess within the past 28 days

- No evidence of active bleeding or bleeding diathesis

- No trauma within the past 28 days

- No nonhealing wound, fracture, or ulcer

- No known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
chemically related to pazopanib hydrochloride

- No psychological, familial, sociological, or geographical condition potentially
hampering compliance with the study protocol and follow-up schedule

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- No ongoing toxicity from prior anticancer therapy that is > grade 1 (except alopecia)
and/or that is progressing in severity

- At least 6 months since prior amiodarone

- At least 14 days since prior CYP3A4 substrates

- At least 2 weeks since prior palliative radiotherapy

- No major surgery within the past 28 days

- No prior multi-target tyrosine kinase inhibitor (TKI), bevacizumab, or cetuximab (as
part of induction therapy)

- Prior radical radiotherapy allowed provided it was at least 12 months from start of
induction chemotherapy for metastatic disease

- Concurrent anticoagulant therapy allowed provided the patient's PT, INR, or PTT is
stable and within the recommended range for the desired level of anticoagulation